Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Wei, L ^a   Zhou, Y ^a   Dai, Q ^a   Qiao, C ^a   Zhao, L ^a   Hui, H ^a   Lu, N ^a   Guo, Q L ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cyclophilin D; Hexokinase II; Mitochondria; Oroxylin A; SIRT3

Indexed keywords

CYCLOPHILIN D; HEXOKINASE; HEXOKINASE ISOENZYME; OROXYLIN A; SIRTUIN 3; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; BREAST CARCINOMA; CANCER CELL CULTURE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; CYCLOPHILINS; FEMALE; FLAVONOIDS; GLYCOLYSIS; HEXOKINASE; HUMANS; MCF-7 CELLS; MITOCHONDRIA; OXIDATIVE STRESS; PLANT ROOTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SCUTELLARIA; SIRTUIN 3;

SCUTELLARIA BAICALENSIS;

EID: 84876900167     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.131     Document Type: Article

References (59)

1. Vousden KH, Prives C. Blinded by the light: The growing complexity of p53. Cell 2009; 137: 413-431.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
3. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
4. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003; 100: 8424-8429.
5. Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harbor Perspect Biol 2010; 2: A000935.
6. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wildtype p53 protein into the mutant conformation. Cell 1991; 65: 765-774.
7. Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol Cell Biol 1991; 11: 12-19.
8. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 2000; 60: 6788-6793.
9. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42-46.
10. Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
11. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspect Biol 2010; 2: A001107.
12. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
13. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
14. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007; 26: 2202-2211.
15. Muller PA, Vousden KH, Norman JC. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209-218.
16. Kim E, Deppert W. Transcriptional activities of mutant p53: When mutations are more than a loss. J Cell Biochem 2004; 93: 878-886.
17. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G. Mutant p53: An oncogenic transcription factor. Oncogene 2007; 26: 2212-2219.
18. Gö hler T, Jäger S, Warnecke G, Yasuda H, Kim E, Deppert W. Mutant p53 proteins bind DNA in a DNA structure-selective mode. Nucleic Acids Res 2005; 33: 1087-1100.
19. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin Y-L et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010; 467: 986-990.
20. Leong C-O, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380.
21. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A et al. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006; 10: 191-202.
22. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010; 17: 273-285.
23. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
24. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science 2003; 301: 336-338.
25. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
26. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
27. Chen C-Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005; 353: 1768-1771.
28. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
29. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 2012; e-pub ahead of print 16 July 2012; doi:10.1038/onc.2012.305.
30. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 2012; 19: 1038-1048.
31. Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H et al. Mutant p53 gain-offunction induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2012; e-pub ahead of print 30 July 2012; doi:10.1038/onc.2012.334.
32. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-198.
33. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006; 12: 2014-2024.
34. Saumet A, Vetter G, Bouttier M, Portales-Casamar E, Wasserman WW, Maurin T et al. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 2009; 113: 412-421.
35. Chhabra R, Dubey R, Saini N. Cooperative and individualistic functions of the microRNAs in the miR-23aB27aB24-2 cluster and its implication in human diseases. Mol Cancer 2010; 9: 232.
36. Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW et al. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011; 15: 2164-2175.
37. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008; 18: 549-557.
38. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
39. Inga A, Storici F, Darden TA, Resnick MA. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002; 22: 8612-8625.
40. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002; 21: 7901-7911.
41. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009; 284: 23204-23216.
42. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11011.
43. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol 2006; 16: 1171-1182.
44. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 2007; 120(Pt 20): 3688-3699.
45. Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/ Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001; 20: 2606-2610.
46. Meloche S, Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene 2007; 26: 3227-3239.
47. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Borresen-Dale AL et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008; 47: 600-607.
48. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462.
49. Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 1998; 18: 3735-3743.
50. Scian MJ, Stagliano KER, Anderson MAE, Hassan S, Bowman M, Miles MF et al. Tumorderived p53 mutants induce NF-kB2 gene expression. Mol Cell Biol 2005; 25: 10097-10110.
51. Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE et al. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 1996; 16: 6009-6019.
52. Wang X, Tang S, Le S-Y, Lu R, Rader JS, Meyers C et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS one 2008; 3: E2557.
53. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-392.
54. Chhabra R, Adlakha YK, Hariharan M, Scaria V, Saini N. Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. PloS one 2009; 4: E5848.
55. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
56. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013; 32: 1252-1265.
57. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10: 4227s-4232s.
58. Richard J, Sainsbury C, Needham G, Farndon J, Malcolm A, Harris A. Epidermal-growthfactor receptor status as predictor of early recurrenceof and death from breast cancer. Lancet 1987; 329: 1398-1402.
59. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P et al. MicroRNA-149., a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 2011; 108: 15840-15845.